EyePoint (EYPT) Other financing activities (2011 - 2026)
EyePoint (EYPT) posted Other financing activities of $606000.0 for Q1 2026, up 72.65% sequentially from $351000.0 in Q4 2025, and up 170.54% YoY from $224000.0 in Q1 2025.
Analysis
EyePoint (EYPT) Other financing activities (2011 - 2026) Analysis & Trends
EyePoint has reported Other financing activities for 14 years, with the latest figure at $606000.0 in Q1 2026.
- Quarterly Other financing activities rose 170.54% year-over-year to $606000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (up 55.45% YoY) and the FY2025 annual result came in at $1.5 million, down 73.39% from the prior year.
- Other financing activities advanced to $606000.0 in Q1 2026 per EYPT's latest filing, from $351000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $4.6 million in Q1 2024 and troughed at -$354000.0 in Q4 2022.
- A 5-year average of $662562.5 and a median of $262000.0 in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2024: Other financing activities tumbled 497.75% in 2022, then jumped 12400.0% in 2024.
- Over 5 years, Other financing activities stood at -$354000.0 in 2022, then jumped by 636.44% to $1.9 million in 2023, then slumped by 95.16% to $92000.0 in 2024, then soared by 281.52% to $351000.0 in 2025, then soared by 72.65% to $606000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $606000.0, $351000.0, and $623000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 597,000.00 |
| Mar 31, 2026 | 606,000.00 |
| Dec 31, 2025 | 351,000.00 |
| Sep 30, 2025 | 623,000.00 |
| Jun 30, 2025 | 273,000.00 |
| Mar 31, 2025 | 224,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Sep 30, 2024 | 251,000.00 |
| Jun 30, 2024 | 625,000.00 |
| Mar 31, 2024 | 4.56 Mn |
| Dec 31, 2023 | 1.90 Mn |
| Sep 30, 2023 | 803,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 248,000.00 |
| Sep 30, 2022 | 154,000.00 |
| Mar 31, 2022 | 241,000.00 |
| Dec 31, 2021 | 89,000.00 |
| Sep 30, 2021 | 101,000.00 |
| Mar 31, 2021 | 183,000.00 |
| Sep 30, 2020 | 107,000.00 |